• Switching from PDE5 inhibitors to riociguat confers benefit in intermediate-risk PAH

    26 days ago - By Healio

    Patients with pulmonary arterial hypertension at intermediate risk who switched from phosphodiesterase type 5 inhibitors to riociguat experienced clinical improvement at 24 weeks, according to results of the REPLACE study.
    Marius M. Hoeper, MD, senior physician in the department of respiratory medicine and professor of pulmonary hypertension at Hannover Medical School and the German Center for Lung Research, and colleagues conducted REPLACE, a prospective, randomized, open-label, 24-week, phase 4, multicenter study to investigate switching from a phosphodiesterase type 5 inhibitor to
    Read more ...